APOE
Apolipoprotein E (APOE ε2 / ε3 / ε4)
アポリポタンパク質E（APOE遺伝子・ε4アレル）
1. Biological & Technical Mechanism
Apolipoprotein E (encoded by the APOE gene on chromosome 19q13.32) is predominantly synthesized by astrocytes and activated microglia in the central nervous system. It mediates cholesterol and phospholipid transport to neurons via low-density lipoprotein (LDL) receptor family members. Humans carry three major polymorphic alleles—ε2, ε3, and ε4—which differ at amino acid positions 112 and 158. Carrying one copy of APOE ε4 increases Alzheimer's disease risk 3- to 4-fold, while homozygosity (ε4/ε4) increases risk 12- to 15-fold and lowers age of onset.
アポリポタンパク質E（第19番染色体 19q13.32 上の APOE 遺伝子によりコードされる）は、中枢神経系において主にアストロサイトおよび活性化ミクログリアで産生され、LDL受容体ファミリーを介して神経細胞へのコレステロールやリン脂質の輸送を担います。ヒトには112番目と158番目のアミノ酸残基の違いによる3つの主要アイソフォーム（ε2, ε3, ε4）が存在します。APOE ε4アレルを1コピー保有するとアルツハイマー病の発症リスクが約3〜4倍、ホモ接合体（ε4/ε4）では約12〜15倍に上昇し、発症年齢も若年化することが確立されています。
2. Open Science & Clinical Trial Significance
In open neuroimaging (ADNI, OpenNeuro) and multi-omics cohorts (Agora AMP-AD), APOE genotype is an essential stratification variable. APOE ε4 accelerates amyloid-beta (Aβ) seeding, impairs perivascular clearance, alters microglial lipid metabolism (lipid-droplet-accumulating microglia), and increases susceptibility to Amyloid-Related Imaging Abnormalities (ARIA-E / ARIA-H) during anti-amyloid monoclonal antibody therapy.
公開脳画像（OpenNeuro, ADNI）やマルチオミクスコホート（Agora AMP-AD）の二次解析において、APOE遺伝子型は最重要の層別化因子（共変量）です。APOE ε4はアミロイドβ（Aβ）の初期凝集促進とクリアランス低下、ミクログリアの脂質代謝異常、血液脳関門（BBB）の脆弱化に関与するほか、抗アミロイドβ抗体医薬投与時におけるアミロイド関連画像異常（ARIA-E / ARIA-H）の発現リスク予測に不可欠な指標となっています。
Related Neuroscience Terms & Standards
Highly sensitive fluid biomarker reflecting both cerebral amyloid-beta plaque burden and early tau tangle phosphorylation in Alzheimer's disease.
Molecular neuroimaging technique using radiolabeled tracers to quantify in vivo protein pathology (amyloid plaques, tau tangles), glucose metabolism, or synaptic density.
High-throughput transcriptomic profiling at individual cell or nucleus resolution, enabling identification of disease-associated microglia (DAM), astrocytes, and vulnerable neuronal subtypes.
Primary composite clinical endpoint in early Alzheimer's disease trials, summing 6 cognitive and functional domains (Memory, Orientation, Judgment, Community, Home, Personal Care; range 0–18).
Open Datasets & Research Publications Related to APOE
Agora Target Validation: APOE (apolipoprotein E) in Alzheimer’s Disease
The protein encoded by this gene is a major apoprotein of the chylomicron. It binds to a specific liver and peripheral cell receptor, and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. This gene maps to chromosome 19 in a cluster with the related apolipoprotein C1 and C2 genes. Mu...
APOE4/4 Reconceptualized as a Distinct Genetically Determined Form of Alzheimer’s Disease
Analysis of over 10,000 cases suggests that APOE4 homozygosity behaves as a distinct, genetically determined form of Alzheimer's disease with near-complete amyloid penetrance, rather than solely a risk factor.
Phenome-wide and proteomic analysis of APOE alleles across different ancestries in the All of Us Research Program
BackgroundApolipoprotein E (APOE) {varepsilon}4 is the strongest common genetic risk factor for Alzheimers disease and a determinant of cardiometabolic risk, yet studies of APOE genotypes with disease associations and plasma proteomic signatures have been primarily restricted to European-ancestry co...
Ancestry-specific effects of APOE on Alzheimer Disease Endophenotypes
INTRODUCTIONAPOE*{varepsilon}4 is the strongest genetic risk factor for Alzheimers disease (AD), yet its effect varies across ancestral populations. As plasma biomarkers increasingly inform AD diagnosis, failure to account for both APOE genotype and genetic ancestry could lead to diagnostic misclass...
APOE Genotype and Fluid Biomarkers of Blood-Brain Barrier Integrity: A Systematic Review and Meta-Analysis
Apolipoprotein E (APOE) genotype is theorised to influence dementia risk partly through effects on blood-brain barrier (BBB) function, but clinical studies examining APOE effects on BBB biomarkers report inconsistent results. Therefore, this systematic review and meta-analysis quantified association...
In APOE4 Carriers, Fibronectin Disturbs the Blood-Brain Barrier
Latest research report from Alzforum on Alzforum Live, APOE Genetics. Analyzes emerging molecular mechanisms, clinical trial outcomes, and diagnostic advances.
Disclaimer: This encyclopedia entry is intended for academic neuroscience research and data science reference only, and does not constitute medical advice.